litlas
Log inCreate account

Peter A. Gottlieb

Active 1987–2025

86
Papers
18,503
Citations
65
h-index
80
i10-index

Citations

Citations per year for Peter A. Gottlieb1990: 1 citations1992: 1 citations1995: 1 citations1996: 4 citations1997: 3 citations1998: 2 citations1999: 3 citations2000: 2 citations2001: 17 citations2002: 15 citations2003: 19 citations2004: 24 citations2005: 35 citations2006: 46 citations2007: 84 citations2008: 127 citations2009: 140 citations2010: 159 citations2011: 137 citations2012: 161 citations2013: 170 citations2014: 121 citations2015: 193 citations2016: 142 citations2017: 151 citations2018: 168 citations2019: 562 citations2020: 591 citations2021: 677 citations2022: 498 citations2023: 517 citations2024: 862 citations2025: 490 citations2026: 14 citations1991: no citations, so this year is not shown1993–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,792 citing papers, 29.9% of this breakdownUnited Kingdom: 501 citing papers, 8.4% of this breakdownChina: 359 citing papers, 6% of this breakdownGermany: 340 citing papers, 5.7% of this breakdownItaly: 316 citing papers, 5.3% of this breakdownCanada: 279 citing papers, 4.7% of this breakdownAustralia: 258 citing papers, 4.3% of this breakdownFrance: 209 citing papers, 3.5% of this breakdownSweden: 191 citing papers, 3.2% of this breakdownNetherlands: 148 citing papers, 2.5% of this breakdownBelgium: 123 citing papers, 2% of this breakdownFinland: 109 citing papers, 1.8% of this breakdown
0%29.9%Other 22.7%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology38.8%
  • Medicine32.7%
  • Immunology and Microbiology23.2%
  • Nursing1.8%
  • Neuroscience1%
  • Psychology0.7%
  • Other1.8%

Topics

  • Diabetes and associated disorders15.2%
  • Pancreatic function and diabetes10.3%
  • T-cell and B-cell Immunology9.9%
  • Immune Cell Function and Interaction9.3%
  • Diabetes Management and Research9%
  • Immunotherapy and Immune Responses3.1%
  • Other43.2%

Coauthors

All papers

Open in search
  1. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Authors: Kevan C. Herold, Brian N. Bundy, S. Alice Long, Jeffrey A. Bluestone, Linda A. DiMeglio, Matthew J. Dufort, Stephen E. Gitelman, Peter A. Gottlieb, Jeffrey P. Krischer, Peter S. Linsley, Jennifer B. Marks, Wayne D. Moore, Antoinette Moran, Henry Rodriguez, William E. Russell, Desmond Schatz, Jay S. Skyler, Eva Tsalikian, Diane K. Wherrett, Anette-Gabriele Ziegler, Carla J. Greenbaum - New England Journal of Medicine 2019 cited by 1,112

  2. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

    Authors: Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jeffrey P. Krischer, Åke Lernmark, Robert E. Ratner, Marian Rewers, Desmond Schatz, Jay S. Skyler, Jay M. Sosenko, Anette‐G. Ziegler - Diabetes Care 2015 cited by 1,148

  3. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

    Authors: Emily K. Sims, Brian N. Bundy, Kenneth Stier, Elisavet Serti, Noha Lim, S. Alice Long, Susan Geyer, Antoinette Moran, Carla J. Greenbaum, Carmella Evans‐Molina, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group, Linda A. DiMeglio, Stephen E. Gitelman, Peter A. Gottlieb, Jennifer B. Marks, Wayne D. Moore, Henry Rodriguez, William E. Russell, Desmond Schatz, Eva Tsalikian, Diane K. Wherrett, Anette‐Gabriele Ziegler - Science Translational Medicine 2021 cited by 359

  4. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

    Authors: Weihong Liu, Amy Putnam, Zhou Xu-yu, Gregory L. Szot, Michael R. Lee, Shirley Zhu, Peter A. Gottlieb, Philipp Kapranov, T Gingeras, Barbara Fazekas de St Groth, Carol Clayberger, David M. Soper, Steven F. Ziegler, Jeffrey A. Bluestone - The Journal of Experimental Medicine 2006 cited by 2,584

  5. Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

    Authors: Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf, Dorothy J. Becker, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Jennifer B. Marks, Paula McGee, Antoinette Moran, Philip Raskin, Henry Rodriguez, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, John M. Lachin, Jay S. Skyler - New England Journal of Medicine 2009 cited by 1,073

  6. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

    Authors: Manuela Battaglia, Simi Ahmed, Mark S. Anderson, Mark A. Atkinson, Dorothy Becker, Polly J. Bingley, Emanuele Bosi, Todd M. Brusko, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Carla J. Greenbaum, Peter A. Gottlieb, Kevan C. Herold, Martin J. Hessner, Mikael Knip, Laura M. Jacobsen, Jeffrey P. Krischer, S. Alice Long, Markus Lundgren, Eoin McKinney, Noel G. Morgan, Richard A. Oram, Tomi Pastinen, Michael C. Peters, Alessandra Petrelli, Xiaoning Qian, María J. Redondo, Bart O. Roep, Desmond Schatz, David Skibinski, Mark Peakman - Diabetes Care 2019 cited by 344

  7. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

    Authors: Tihamer Orban, Brian N. Bundy, Dorothy J. Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Jennifer B. Marks, Roshanak Monzavi, Antoinette Moran, Philip Raskin, Henry Rodriguez, William E. Russell, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler - The Lancet 2011 cited by 601

  8. Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

    Authors: Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum, William Hagopian, Karen D. Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H. Sayre, James McNamara, Jeffrey A. Bluestone, and the AbATE Study Team - Diabetes 2013 cited by 405

  9. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

    Authors: William E. Russell, Brian N. Bundy, Mark S. Anderson, Laura A. Cooney, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Michael J. Haller, Jeffrey P. Krischer, Ingrid Libman, Peter S. Linsley, S. Alice Long, Sandra Lord, Daniel J. Moore, Wayne V. Moore, Antoinette Moran, Andrew Muir, Philip Raskin, Jay S. Skyler, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, Anette‐Gabriele Ziegler, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group - Diabetes Care 2023 cited by 96

  10. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

    Authors: Mark Rigby, Kristina M. Harris, Ashley Pinckney, Linda A. DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou, Stephen E. Gitelman, Kurt Griffin, Eva Tsalikian, Peter A. Gottlieb, Carla J. Greenbaum, Nicole Sherry, Wayne V. Moore, Roshanak Monzavi, Steven M. Willi, Philip Raskin, Lynette Keyes-Elstein, S. Alice Long, Sai Kanaparthi, Noha Lim, Deborah Phippard, Carol L. Soppe, Margret L. Fitzgibbon, James McNamara, Gerald T. Nepom, Mario R. Ehlers, the Immune Tolerance Network (ITN) T1DAL Study Group - Journal of Clinical Investigation 2015 cited by 292

  11. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

    Authors: Kevan C. Herold, Stephen E. Gitelman, Peter A. Gottlieb, Laura A. Knecht, Ralph Raymond, Eleanor L. Ramos - Diabetes Care 2023 cited by 123

  12. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

    Authors: Michael J. Haller, Desmond Schatz, Jay S. Skyler, Jeffrey P. Krischer, Brian N. Bundy, Jessica Miller, Mark A. Atkinson, Dorothy J. Becker, David A. Baidal, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, Antoinette Moran, Henry Rodriguez, William E. Russell, Darrell M. Wilson, Carla J. Greenbaum, Type 1 Diabetes TrialNet ATG-GCSF Study Group, Carla J. Greenbaum, Mark A. Atkinson, David A. Baidal, M. Battaglia, Dorothy Becker, P. J. Bingley, Emanuele Bosi, Jan C. Buckner, Mark A. Clements, Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Mikael Knip, J. Krischer, Åke Lernmark, W. Moore, Antoinette Moran, Andrew J. Muir, J. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, W. J. Russell, Lisa M. Spain, Desmond Schatz, Jay M. Sosenko, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Mark S. Anderson, Peter A. Antinozzi, Christophe Benoıst, J.J. Blum, Kasia Bourcier, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, Catherine C. Cowie, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, L. Harrison, Bernhard J. Hering, Richard A. Insel, Sabine D. Jordan, Francine Kaufman, Tom Kay, Norma S. Kenyon, R. Klines, John M. Lachin, Ellen Leschek, Jeff Mahon, Jennifer B. Marks, Roshanak Monzavi, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, A. Pugliese, John A. Ridge, Bart O. Roep, Maria Grazia Roncarolo, Peter J. Savage, Olli Simell, R S Sherwin, Mark Siegelman, Jay S. Skyler, Andrea K. Steck, James W. Thomas, Massimo Trucco and 212 more - Diabetes Care 2018 cited by 180

  13. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: Stephen E. Gitelman, Brian N. Bundy, Ele Ferrannini, Noha Lim, Lori Blanchfield, Linda A. DiMeglio, Eric I. Felner, Jason L. Gaglia, Peter A. Gottlieb, S. Alice Long, Andrea Mari, Raghavendra G. Mirmira, Philip Raskin, Srinath Sanda, Eva Tsalikian, John M. Wentworth, Steven M. Willi, Jeffrey P. Krischer, Jeffrey A. Bluestone, Mayalin Barr, Lori Blanchfield, Jeffrey A. Bluestone, Jeanne Buchanan, Brian N. Bundy, Joanne Cabbage, Peter G. Coleman, Monica De La Vega, Linda A. DiMeglio, Carmella Evans‐Molina, Eric I. Felner, Ele Ferrannini, Christine Ferrara, Jason L. Gaglia, Stephen E. Gitelman, Peter A. Gottlieb, Felicity Healy, Laurie Higgins, Megan Hildinger, Margaret A. Jenkins, Nora Bryant, Amanda Kinderman, Nisha Koshy, Brianne Kost, Jeffrey P. Krischer, Suzanne Krishfield, Olena Kucheruk, Noha Lim, Karen L. Lindsley, S. Alice Long, Manasa Mantravadi, Andrea Mari, Shelley Mesfin, Aaron W. Michels, Mary Ellen Migre, Pantea Minnock, Raghavendra G. Mirmira, Elham Mohammed-Nur, Jennifer B. Nelson, Ashvin Nursing, Ryan O’Donnell, Diana R. Olivos, Melissa M. Parker, Philip Raskin, Leanne Redl, Nicole Reed, Brittany Resnick, Srinath Sanda, Peter H. Sayre, Elisavet Serti, Emily Sims, Karen Smith, Carol L. Soppe, Fiona Stuart, Sarah Szubowicz, Michel Tansey, Jennifer Terrell, Sarah A. Tersey, Christine Torok, Eva Tsalikian, Kelly Watson, John M. Wentworth, Rebecca Wesch, Steven M. Willi, Stéphanie Woerner - The Lancet Diabetes & Endocrinology 2021 cited by 133

  14. B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

    Authors: Mark D. Pescovitz, Carla J. Greenbaum, Brian N. Bundy, Dorothy J. Becker, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Jennifer B. Marks, Antoinette Moran, Philip Raskin, Henry Rodriguez, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler, the Type 1 Diabetes TrialNet Anti-CD20 Study Group - Diabetes Care 2013 cited by 282

  15. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

    Authors: María J. Redondo, Susan Geyer, Andrea K. Steck, Seth A. Sharp, John M. Wentworth, Michael N. Weedon, Peter A. Antinozzi, Jay M. Sosenko, Mark A. Atkinson, Alberto Pugliese, Richard A. Oram, Type 1 Diabetes TrialNet Study Group, Peter A. Antinozzi, Mark A. Atkinson, Manuela Battaglia, Dorothy J. Becker, P. J. Bingley, Emanuele Bosi, Jan C. Buckner, Peter G. Colman, Peter A. Gottlieb, Kevan C. Herold, Richard A. Insel, Tom Kay, Mikael Knip, Jennifer B. Marks, Antoinette Moran, James L. Palmer, Mark Peakman, Louis H. Philipson, Alberto Pugliese, P. Raskin, Henry Rodriguez, Bart O. Roep, William E. Russell, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Christophe Benoıst, J.J. Blum, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, Bernhard J. Hering, Francine Kaufman, Ellen Leschek, J. Mahon, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, Maria Grazia Roncarolo, Olli Simell, Robert Sherwin, Mark Siegelman, Andrea K. Steck, James W. Thomas, Massimo Trucco, J. Richard Wagner, Carla J. Greenbaum, Katarzyna Bourcier, Richard A. Insel, Jeffrey P. Krischer, Ellen Leschek, Lisa Rafkin, Lisa M. Spain, Catherine C. Cowie, Mary A. Foulkes, Heidi Krause‐Steinrauf, John M. Lachin, Saúl Malozowski, John Peyman, J P Ridge, Peter J. Savage, Jay S. Skyler, Stephanie J. Zafonte, Norma S. Kenyon, Irene Santiago, Jay M. Sosenko, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, Brian N. Bundy, Cristina Burroughs, David Cuthbertson, Mary Deemer, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson and 1,520 more - Diabetes Care 2018 cited by 169

  16. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

    Authors: Michael J. Haller, S. Alice Long, J. Lori Blanchfield, Desmond Schatz, Jay S. Skyler, Jeffrey P. Krischer, Brian N. Bundy, Susan Geyer, Megan Warnock, Jessica Miller, Mark A. Atkinson, Dorothy J. Becker, David A. Baidal, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, Antoinette Moran, Henry Rodriguez, William E. Russell, Darrell M. Wilson, Carla J. Greenbaum, Type 1 Diabetes TrialNet ATG-GCSF Study Group, Carla J. Greenbaum, Mark A. Atkinson, David A. Baidal, Manuela Battaglia, Dorothy J. Becker, P. J. Bingley, Emanuele Bosi, Jane H. Buckner, Mark A. Clements, Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter Gottlieb, Kevan C. Herold, Mikael Knip, Jeffrey P. Krischer, Åke Lernmark, Wayne D. Moore, Antoinette Moran, Andrew J. Muir, Jerry P. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, William E. Russell, Desmond A. Schatz, Jay M. Sosenko, Lisa M. Spain, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette G. Ziegler, Mark S. Anderson, Peter A. Antinozzi, Richard A. Insel, Thomas W. H. Kay, Jennifer B. Marks, Alberto Pugliese, Bart O. Roep, Jay S. Skyler, Jorma Toppari, Carla J. Greenbaum, Jeffrey P. Krischer, Ellen Leschek, Lisa Spain, Katarzyna Bourcier, Richard A. Insel, J P Ridge, Jay S. Skyler, Carla J. Greenbaum, Lisa Rafkin, Jay M. Sosenko, Jay S. Skyler, Irene Santiago, Jeffrey P. Krischer, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Ilma Asif, Jenna Bjellquist, Matthew Boonstra, Cristina Burroughs, Mario Cleves, David Cuthbertson, Meagan DeSalvatore, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Susan Geyer and 178 more - Diabetes 2019 cited by 131

  17. Fall in C-Peptide During First 2 Years From Diagnosis

    Authors: Carla J. Greenbaum, Craig A. Beam, David Boulware, Stephen E. Gitelman, Peter A. Gottlieb, Kevan C. Herold, John M. Lachin, Paula McGee, Jerry P. Palmer, Mark D. Pescovitz, Heidi Krause‐Steinrauf, Jay S. Skyler, Jay M. Sosenko, on behalf of the Type 1 Diabetes TrialNet Study Group - Diabetes 2012 cited by 320

  18. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

    Authors: Kevan C. Herold, Stephen E. Gitelman, Steven M. Willi, Peter A. Gottlieb, Frank Waldron-Lynch, Lesley Devine, Jennifer L. Sherr, S. M. Rosenthal, S. Adi, Muhammad Yazid Jalaludin, Aaron W. Michels, J. Dziura, Jeffrey A. Bluestone - Diabetologia 2012 cited by 157

  19. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

    Authors: the Immune Tolerance Network, Ana Luisa Perdigoto, Paula Preston‐Hurlburt, Pamela Clark, S. Alice Long, Peter S. Linsley, Kristina M. Harris, Steven Gitelman, Carla J. Greenbaum, Peter A. Gottlieb, William Hagopian, Alyssa Woodwyk, James Dziura, Kevan C. Herold - Diabetologia 2018 cited by 125

  20. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes

    Authors: Christine Bender, Alice Wiedeman, Alex Hu, Alyssa Ylescupidez, William K. Sietsema, Kevan C. Herold, Kurt Griffin, Stephen E. Gitelman, S. Alice Long, on behalf of the T-Rex Study Group†, Peter A. Gottlieb, R. Strock, Lexie Chesshir, María J. Redondo, Christopher T. Williams, Mark A. Clements, Wayne V. Moore, Linda A. DiMeglio, Megan Legge, M. Mullen, Juan Manuel Sepúlveda-Sánchez, Maria Spall, Stéphanie Woerner, Jason L. Gaglia, Brittany Resnick, Nora Bryant, Suzanne Krishfield, J J Turley, Nisha Koshy, Mikayla Mackey, Ines Guttmann‐Bauman, Rebecca Fitch, Lynn Bartholow, John Shelso, Alaa Al Nofal, K. Hanisch, Luis E. De Las Casas, Brenda Thurlow, Michael Gottschalk, Marla Hashiguchi, Lisa Paglia, Angela Y. Lam, Srinath Sanda, Christine Torok, Rebecca Wesch, Daniel J. Moore, William E. Russell, Tyler Jordan Smith, Anne Brown, Faith Brendle, Michael J. Haller, Miriam Cintrón, David A. Baidal, Della Matheson, Carlos Blaschke, Antoinette Moran, Elizabeth Pappensus, Janice Leschyshyn, Anne Street - Science Translational Medicine 2024 cited by 65

  21. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

    Authors: Diane K. Wherrett, Brian N. Bundy, Dorothy J. Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jennifer B. Marks, Roshanak Monzavi, Antoinette Moran, Tihamer Orban, Jerry P. Palmer, Philip Raskin, Henry Rodriguez, Desmond Schatz, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler - The Lancet 2011 cited by 369

  22. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes

    Authors: Janet M. Wenzlau, Kirstine Juhl, Liping Yu, Ong Moua, Suparna A. Sarkar, Peter A. Gottlieb, Marian Rewers, George S. Eisenbarth, Jan Jensen, Howard W. Davidson, John C. Hutton - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 997

  23. Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes

    Authors: Aimon K. Alkanani, Naoko Hara, Peter A. Gottlieb, Diana Ir, Charles E. Robertson, Brandie D. Wagner, Daniel N. Frank, Danny Zipris - Diabetes 2015 cited by 297

  24. Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

    Authors: Ronnie Aronson, Peter A. Gottlieb, Jens Sandahl Christiansen, Thomas Donner, Emanuele Bosi, Bruce W. Bode, Paolo Pozzilli, the DEFEND Investigator Group - Diabetes Care 2014 cited by 150